Accessibility Menu
Eisai logo

Eisai(OTC) ESAIY

Market Cap$8.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-51%
5 Year-90%
1 Year+2%
1 Month+14%
$7.57
-0.42%
-0.03Today
Eisai last closing stock price
MetricPriceDate
Last closeUSD 7.602026-08-13
Eisai stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.11%USD 7.302026-08-06
1 month+13.77%USD 6.682026-07-14
3 month+5.85%USD 7.182026-05-15
Year to date+4.69%USD 7.262025-12-31
1 year+2.16%USD 7.442025-08-13
3 year-49.66%USD 15.102023-08-14
5 year-89.65%USD 73.462021-08-13
Since inception-51.03%USD 15.522023-02-02

Eisai Financials at a Glance

Market Cap

$8.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥871.33B

Net Income (TTM)

¥42.99B

EPS (TTM)

$0.24

P/E Ratio

31.28

Dividend

$0.25

Beta (Volatility)

0.24 (Low)

Price

$7.57

Volume

5,286

Open

$7.55

Previous Close

$7.60

Daily Range

$7.55 - $7.59

52-Week Range

$5.69 - $9.22

Estimated Earnings Date

May 13, 2026

ESAIY News

Medical personnel preparing an injection.

What Are the Clinical Development Phases?

Benjamin LockeAug 16, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eisai

Eisai Co., Ltd. is a Japanese pharmaceutical company engaged in the full lifecycle of drug development, from research to distribution. The firm specializes in innovative treatments, particularly in oncology and neurology, with a strong commitment to improving patient outcomes.

Products and Services
  • Dayvigo for insomnia management
  • Lenvima, an anticancer therapy for multiple cancers
  • Aricept, a treatment for Alzheimer's disease
Growth Outlook
  • Recent partnerships enhance drug development capabilities
  • Focus on expanding oncology portfolio to meet market demand
  • Investment in R&D expected to drive future product launches
Financial Highlights
  • TTM revenue of 1.01 trillion JPY, reflecting strong market presence
  • Net income of 17.49 billion JPY in Q3 2025, indicating recovery
  • Operating cash flow of 28.6 billion JPY in Q4 2025, supporting liquidity
Eisai Co., Ltd. has established itself as a key player in the pharmaceutical industry, particularly in the fields of oncology and neurology. The company's diverse product portfolio includes well-known medications that address significant health challenges. Recent financial performance indicates a positive trajectory, with a notable recovery in net income and robust operating cash flow. The strategic focus on research and development, along with partnerships, positions Eisai for continued growth and innovation in the healthcare sector. Investors may find the company's commitment to improving patient outcomes and expanding its product offerings appealing as it navigates the evolving pharmaceutical landscape.
AI Generated • Jul 27, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

10,543

CEO

Haruo Naito

Website

www.eisai.co.jp

Headquarters

Tokyo, TY 112-8088, JP

ESAIY Financials

Key Financial Metrics (TTM)

Gross Margin

76.70%

Operating Margin

5.11%

Net Income Margin

4.94%

Return on Equity

4.77%

Return on Capital

4.05%

Return on Assets

2.72%

Earnings Yield

3.20%

Dividend Yield

3.34%

Payout Ratio

1.07%

Stock Overview

Market Cap

$8.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.13B

Volume

5.29K

Avg. Volume

223.11K

Financials (TTM)

Gross Profit

¥668.27B

Operating Income

¥44.47B

EBITDA

¥94.82B

Operating Cash Flow

¥58.85B

Capital Expenditure

-¥10.59B

Free Cash Flow

¥48.26B

Cash & ST Invst.

¥309.68B

Total Debt

¥269.55B

Eisai Performance Analysis

Eisai annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31JPY 5,495,248,038-18.3%
20242024-03-31JPY 5,136,302,320-6.5%
20252025-03-31JPY 5,178,078,7190.8%
20262026-03-31JPY 5,477,248,5255.8%
Eisai sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-1.1%
Q32025-12-3111.5%
Q42026-03-31-6.6%
Q12026-06-3013.5%
Eisai annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31JPY 0.36-4.1%
20242024-03-31JPY 0.26-28.2%
20252025-03-31JPY 0.274.9%
20262026-03-31JPY 0.23-15.5%
Eisai sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30-29.6%
Q32025-12-3169.3%
Q42026-03-31-119.0%
Q12026-06-30649.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

¥237.42B

+16.9%

Gross Profit

¥185.65B

+15.7%

Gross Margin

78.20%

N/A

Market Cap

$8.59BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$814.45K

N/A

Employees

10,543

N/A

Net Income

¥18.48B

+27.4%

EBITDA

¥34.57B

+4.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

¥309.68B

+8.5%

Total Debt

¥269.55B

+12.8%

Accounts Receivable

¥251.45B

+14.3%

Inventory

¥280.15B

+23.2%

Long Term Debt

¥183.39B

+83.7%

Short Term Debt

¥86.17B

-38.0%

Return on Assets

2.72%

N/A

Return on Invested Capital

3.76%

N/A

Free Cash Flow

-¥6.94B

+13.2%

Operating Cash Flow

-¥2.62B

-339.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GIFLFGrifols, S.A.
$11.76+0.00%
WILLFDemant A/S
$44.88+0.00%
KYKOFKyowa Kirin Co., Ltd.
$14.43+0.00%
WILYYDemant A/S
$23.00+2.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.21+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.60-0.00%
ONDSOndas
$9.20+0.03%
INTCIntel
$103.10-0.01%

Questions About ESAIY

What is the current price of Eisai?

Eisai is trading at $7.57 per share.

What is the 52-week range for Eisai?

Over the past 52 weeks, Eisai has traded between $5.69 and $9.22.

How much debt does Eisai have?

As of the most recent reporting period, Eisai reported total debt of ¥1.67B.

How much cash does Eisai have on hand?

Eisai reported ¥1.92B in cash and cash equivalents in its most recent financial results.

What is Eisai’s dividend yield?

Eisai currently has a dividend yield of 3.34%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services